Everything we know about Hayat-Vax as distribution of UAE's Covid-19 vaccine begins
Hayat-Vax is the locally-produced version of the Sinopharm vaccine
A technician oversees the production of the UAE's version of the Sinopharm vaccine - named Hayat-Vax - at drug maker Julphar's plant in Ras Al Khaimah. All photos are screengrabs of a video courtesy of G42 Healthcare / Julphar
"We believe that every person has the right to obtain the vaccine without discrimination," he said at an online conference hosted by the Hope Consortium, an Abu Dhabi-based logistics collective set up to deliver vaccines around the world.
Experts have said that help is much needed.
As of last week, Covax had only shipped about 50 million of the two billion doses it aims to distribute globally this year.
India was expected to supply half of the total with its Covishield vaccine, a locally-produced version of the AstraZeneca vaccine, but it has stopped exports due to the surge in new cases there.
Deliveries by Pfizer-BioNTech have reportedly been limited, and Johnson & Johnson’s vaccine has not yet shipped. Moderna’s vaccine was only listed by the WHO shortly before the Sinopharm vaccine.
Hayat-Vax, which can be kept at normal fridge temperatures, is easier to use in low income countries than the mRNA vaccines, which need ultra-cold storage.
Most of Africa, for example, relies on Covax for its supply. It lacks the infrastructure to store Pfizer-BioNTech and Moderna vaccines, making Hayat-Vax more suitable for distribution there.
Where is the Sinopharm vaccine in use?
It has been approved for use in 45 countries and more than 65 million doses have been administered so far.
The UAE became the first country in the world to grant approval to the vaccine, after a successful large-scale Phase 3 clinical trial. The vaccine was found to have 78 per cent efficacy by WHO.
The vaccine is 100 per cent effective at preventing death, 93 per cent effective in preventing the need for hospitalisation care and 95 per cent effective against admission to intensive care, according to research conducted in Abu Dhabi, where the vaccine has accounted for the overwhelming bulk of Covid-19 shots.
It was the sole vaccine used in Abu Dhabi until the Pfizer-BioNTech was approved last month.